Gilead Sciences to acquire Arcellx for 7.8 billion dollars
Gilead Sciences announced on Monday that it will acquire cancer drug developer Arcellx. The deal features an implied equity value of 7.8 billion dollars.
Insights:
Gilead Sciences, Inc. announced today, February 23, 2026, that it will acquire Arcellx, Inc. for an implied equity value of $7.8 billion. This transaction represents a large-scale corporate acquisition in the cancer drug development (oncology) sector, marking a significant expansion for Gilead and a material company-level action for both entities involved.
